Ivax taps former Lederle head Bethune as president, Novopharm's Henein as Zenith Goldline CEO.
Executive Summary
ZENITH GOLDLINE CEO HENEIN JOINS COMPANY FROM NOVOPHARM, where he was CEO of Novopharm International with responsibility for Novopharm's activities in the U.S. and worldwide outside of Canada. Rafick Henein, PhD, will succeed William Schreck as head of the Ivax generic pharmaceuticals business. Henein's start date has not been set, Zenith said. Ivax hopes to retain Schreck in a senior management position. Henein is departing Novopharm as the Canadian company is launching the first generic version of Glaxo Wellcome's Zantac .